Study summary
A gene-silencing drug that also raises hepcidin cut blood draws to nearly zero
0median phlebotomies in 20 weeks, down from 5
What was tested
Sapablursen, an antisense drug that switches off TMPRSS6 to raise the body's own hepcidin, for polycythemia vera needing phlebotomies.
What they found
- Median phlebotomies fell from 5.0 to 0 in the main group.
- Symptom scores improved.
- Side effects were mostly mild, mainly anemia and fatigue.
What it means
A second way to reach the same target as rusfertide, now in the phase 3 INTREPID trial.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.